At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Pegcetacoplandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN
In Brief
A Phase 2 clinical trial evaluating Pegcetacoplan for C3G and 11 related conditions. Completed, enrolled 13 participants across 25 sites in 11 countries.
Detailed Summary
This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsC3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
CountriesArgentina, Australia, Austria, Brazil, France, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartSep 2021
Primary CompletionFeb 2023
Study CompletionJan 2026
TodayJul 2026
First PostedOct 1, 2020
Enrollment StartSep 7, 2021
Primary CompletionFeb 27, 2023
Study CompletionJan 20, 2026
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.8 years ago
Interventions
Pegcetacoplandrug
Complement (C3) Inhibitor